| WB | 1/2000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | Protein lyl-1, Class A basic helix-loop-helix protein 18, bHLHa18, Lymphoblastic leukemia-derived sequence 1, LYL1, BHLHA18 |
| Entrez GeneID | 4066 |
| WB Predicted band size | 29.9kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | This LYL1 antibody is generated from a rabbit immunized with a KLH conjugated synthetic peptide between 212-244 amino acids from human LYL1. |
+ +
以下为虚构示例的参考文献格式(非真实文献，仅供格式参考)：
1. **《LYL1在急性淋巴细胞白血病中的调控机制研究》**
作者：Smith J, et al.
摘要：研究利用LYL1特异性抗体检测患者样本，发现LYL1过表达通过激活Notch信号通路促进白血病细胞增殖，提示其作为潜在治疗靶点。
2. **《LYL1抗体在实体瘤诊断中的应用评估》**
作者：Zhang L, et al.
摘要：开发了一种高特异性LYL1单克隆抗体，验证其在乳腺癌和肺癌组织中的表达差异，表明LYL1可能参与肿瘤上皮-间质转化过程。
3. **《LYL1与血管生成相关性的分子机制》**
作者：Brown K, et al.
摘要：通过免疫组化(LYL1抗体)和基因敲除实验，揭示LYL1通过调控VEGF通路影响血管内皮细胞分化，为血管疾病提供新见解。
4. **《LYL1抗体在造血干细胞分化中的功能研究》**
作者：Wang Y, et al.
摘要：利用LYL1抗体阻断实验，证明LYL1在造血干细胞向淋巴系分化中起关键作用，缺失导致分化停滞及凋亡增加。
---
**注意**：以上内容为模拟示例，实际文献需通过PubMed、Google Scholar等平台检索关键词"LYL1 antibody"或"LYL1 function"获取。近期研究可能涉及表观遗传调控或临床前模型验证。
The LYL1 (lymphoblastic leukemia-derived sequence 1) antibody is a tool used to detect the LYL1 protein, a basic helix-loop-helix (bHLH) transcription factor implicated in hematopoiesis and leukemogenesis. Discovered through its involvement in T-cell acute lymphoblastic leukemia (T-ALL), LYL1 is structurally related to the TAL1/SCL oncogene. It forms heterodimers with E-proteins (e.g., E2A) via its bHLH domain, binding E-box DNA motifs to regulate gene expression. While its physiological role remains less defined, LYL1 is expressed in hematopoietic stem/progenitor cells and endothelial cells, suggesting functions in normal blood development and vascular biology.
In leukemia, aberrant LYL1 expression, often due to chromosomal translocations (e.g., t(7;19)(q35;p13)), disrupts differentiation and promotes malignant proliferation. Mouse models show that LYL1 overexpression induces T-ALL-like diseases, highlighting its oncogenic potential. LYL1 antibodies are critical for research applications, including Western blotting, immunohistochemistry, and flow cytometry, enabling studies on its expression patterns, interaction partners, and regulatory mechanisms. Clinically, LYL1 detection may aid in leukemia subtyping, though its utility as a standalone diagnostic marker is limited. Recent studies also explore LYL1's role in solid tumors and its interplay with NOTCH signaling, broadening its relevance in oncology. Commercial LYL1 antibodies vary in specificity; validation using knockout controls is essential to ensure reliability.
×
